# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN
- Date: 2026-02-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two weeks after starting losartan: potassium, creatinine and blood pressure, and the decision about dapagliflozin. **S**

## History of present illness

Mrs. Wells returns two weeks after starting losartan 50 mg, atorvastatin and vitamin D3. She has had no dizziness, cough or swelling of the lips. Her home readings average 140/84. Her ankles swell less. She met the dietitian this morning and is cutting salt, and she has read about SGLT2 inhibitors and asked how much they lower the risk of kidney failure; the trial evidence in people with and without diabetes was explained. She wants to start. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 140/84 |
| Side effects | None |
| Diet | Dietitian session this morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Still tired in the afternoons, a little less |
| Cardiovascular | Negative | Less ankle swelling; no chest pain |
| Neurological | Negative | No dizziness on standing |
| Genitourinary | Negative | No burning or genital itching |

4 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen **S**
- Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 142/84 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 69.6 kg; BMI 28.2 kg/m². All vital signs are synthetic.

Sodium: 138 mmol/L; Potassium: 4.9 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 30 mg/dL (high); Creatinine: 1.5 mg/dL (high); eGFR, creatinine (CKD-EPI 2021, race-free): 38 mL/min/1.73 m² (low). All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 4.9 mmol/L at this visit **S**
- Bicarbonate (total CO2): 22 mmol/L at baseline, 22 mmol/L at this visit **S**
- Urea nitrogen: 28 mg/dL (high) at baseline, 30 mg/dL (high) at this visit **S**
- Creatinine: 1.42 mg/dL (high) at baseline, 1.5 mg/dL (high) at this visit **S**
- eGFR, creatinine (CKD-EPI 2021, race-free): 40 mL/min/1.73 m² (low) at baseline, 38 mL/min/1.73 m² (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 142/84, pulse 74; weight 69.6 kg |
| Cardiovascular | Regular rhythm; no ankle swelling today |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3b A2** (N18.32). Potassium 4.9 mmol/L and creatinine 1.50 mg/dL (eGFR 38, from 40): the expected small rise on losartan, well under 30%. Safe to add an SGLT2 inhibitor, which KDIGO recommends with albuminuria of 200 mg/g or more. **S**
   - Dapagliflozin 10 mg daily, with sick-day rules.
   - Potassium and creatinine in four weeks.
   - No potassium restriction at present.
2. **Hypertension with chronic kidney disease** (I12.9). Improving, not at goal; dapagliflozin will lower it slightly; losartan to be increased once kidney function is stable on both. **S**
   - Home readings the week before the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated cuff, average of two readings) | Every visit | Completed today | 142/84 |
| Self-management | Home blood pressure readings | Seven days to confirm; then the week before each visit while medicines change | Completed today | Average 140/84 |
| Laboratory | Potassium, sodium, bicarbonate, urea nitrogen, creatinine and eGFR | Two to four weeks after starting or increasing an ARB or SGLT2 inhibitor; then with each eGFR check (about twice a year at G3b A2) | Completed today | Two weeks after losartan: sodium 138, potassium 4.9, bicarbonate 22 mmol/L; urea nitrogen 30, creatinine 1.50 mg/dL; eGFR 38 |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; three to six months after a treatment change; then about twice a year at G3b A2 | Up to date | 228 mg/g two weeks ago; next three months after treatment began |
| Medication safety | Medication review: NSAIDs, contrast, dose adjustment, sick-day rules | Every visit | Completed today | No NSAIDs; acetaminophen within limits; sick-day rules for dapagliflozin added |
| Medication safety | Medicine safety: dizziness, genital infection, urine volume, sick-day rules | After starting an SGLT2 inhibitor | Completed today | Expected rise in urine volume and a small eGFR dip explained; genital hygiene advice; hold on sick days and before procedures |
| Self-management | Lifestyle: sodium below 2 g a day, activity, plant-rich diet | Every visit | Completed today | Dietitian session today: sodium below 2 g, protein about 0.8 g per kg, plant-rich meals |
| Laboratory | Hemoglobin | At least yearly at G3; recheck in three months when mildly low | Up to date | 11.2 g/dL at intake; recheck in three months |
| Laboratory | Calcium, phosphate, intact PTH and 25-hydroxyvitamin D | Baseline at G3; then every 6 to 12 months; vitamin D and PTH three months after starting replacement | Up to date | Vitamin D3 started two weeks ago; recheck in three months |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within two months of starting treatment, and lower if tolerated. In progress; target 2026-03-03. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% at the three-month check on treatment. In progress; target 2026-03-03. **S**
- No NSAIDs or other avoidable kidney harms; every medicine checked against her kidney function. In progress; target 2026-03-03. **S**
- An informed decision about APOL1 genetic testing, made by her after counseling. Outcome by 2026-01-20: Counseled at the consultation; she chose to defer the test and may ask for it at any time. **S**
- She understands her stage, her risk and the kidney replacement options, and her wishes are recorded, long before any decision is needed. In progress; target 2026-02-17. **S**

## Medication changes

- Started: Dapagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026), Aether Forge

## Follow-up

- Annual wellness visit in two weeks. Potassium and creatinine in four weeks. Call for dizziness, fainting, vomiting or diarrhea (hold dapagliflozin and losartan that day), or genital itching. **S**
- Next scheduled visit 2026-02-17: subsequent annual wellness visit. **S**
